Reports
Sale
Dyslipidemia Market Size, Share, Trends, Growth, Report: By Disease Type: General dyslipidemia, Hyperlipidemia, Combined hyperlipidemia, Hypoalphalipoproteinemia; By Drug Type: Statin Drugs, Non-Statin Lipid–Lowering Drugs; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Dyslipidemia Market Outlook
The dyslipidemia market size was valued at USD 10.2 billion in 2023, driven by the emphasis on preventing cardiovascular diseases across the major markets. The market is expected to grow at a CAGR of 6.7% during the forecast period of 2024-2032, with the values likely to rise from USD 10.8 billion in 2024 to USD 18.2 billion by 2032.
Dyslipidemia: Introduction
Dyslipidemia is a condition characterized by abnormal levels of lipids in the bloodstream. The most common forms of dyslipidemia involve high levels of bad cholesterol (LDL), triglycerides or low levels of good cholesterol (HDL). Untreated or severe dyslipidemia may lead to coronary artery disease (CAD) or peripheral artery disease (PAD). Based on cause, it can be categorized into two broad categories, primary dyslipidemia, which is inherited, and secondary dyslipidemia, which is caused by lifestyle factors. Treatment for dyslipidemia constitutes medications and lifestyle changes to control cholesterol levels naturally.
Dyslipidemia Market Analysis
The increasing development of drugs and new therapeutics to treat the condition are increasingly contributing to the dyslipidemia market share. Ezetimibe is frequently used in combination with statins and has shown significant reductions in LDL cholesterol levels. Alirocumab (Praluent) is a human immunoglobulin G1 monoclonal antibody while Evolocumab is another monoclonal G2 antibody belonging to PCSK9 category. Bempedoic acid is another key agent that decreases LDL-C levels and showcases evidence of good tolerability and safety.
With advanced research and ongoing clinical trials, scientists are also working on using the potential of ASOs to impact mRNA and provide new avenues for the treatment of persistent disorders. Therefore, there is hope for treating primary dyslipidemia as well, especially with the rising advances in gene therapies. Such efforts in research and development, along with increased support from governments and healthcare organizations are likely to aid the dyslipidemia market demand in the coming years.
Dyslipidemia Market Segmentation
Market Breakup by Disease Type
-
General dyslipidemia
- Hyperlipidemia
- Combined Hyperlipidemia
- Hypoalphalipoproteinemia
Market Breakup by Drug Type
- Statin Drugs
- Non-Statin Lipid–Lowering Drugs
Market Breakup by Drug Type
- Generic
- Branded
Market Breakup by Distributor Channel
- Hospital Pharmacy
- Online pharmacy
- Retail Pharmacy
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Dyslipidemia Market Overview
With the rising prevalence of obesity, sedentary lifestyle habits, unhealthy dietary changes and tobacco consumption, the United States is at a higher risk of developing cardiovascular diseases. As a result, the region is expected to lead the dyslipidemia market share in the forecast period. The existence of regulatory authorities such as the FDA plays a pivotal part in maintaining the quality and efficacy of drugs being launched in the market. This can be a major factor in the growing market value in the region.
Owing to a high percentage of the geriatric population, Europe is another major market for dyslipidemia. With a robust healthcare ecosystem as well as proactive government, there are several awareness and educational campaigns launched in the region, explaining the maintenance of a healthy heart. The market growth is further enhanced by the presence of key healthcare and academic institutions that continuously conduct clinical trials to determine the efficacy of treatments.
In Asia Pacific, the dyslipidemia market growth is certain with the increasing investment in healthcare research and development infrastructure. The region is witnessing numerous mergers and acquisitions between native and foreign companies that aim to leverage the academic expertise pertaining to the region while offering the latest technologies to develop quality solutions. In addition, the government is also aiding market growth by facilitating easy accessibility of relevant to the people in need at affordable prices.
Dyslipidemia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer, Inc.
- Novartis AG
- AstraZeneca plc
- Amgen, Inc.
- Abbott Laboratories.
- Bayer AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Mylan N.V.
- Shionogi & Co., Ltd.
- Catabasis Pharmaceuticals
- DAIICHI SANKYO COMPANY, LIMITED
- Eli Lilly and Company
- GlaxoSmithKline plc
- ESPERION Therapeutics, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Drug Type |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Dyslipidemia Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Dyslipidemia Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Dyslipidemia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Dyslipidemia Epidemiology Forecast (2017-2032)
5.3.1 Germany Dyslipidemia Epidemiology Forecast (2017-2032)
5.3.2 France Dyslipidemia Epidemiology Forecast (2017-2032)
5.3.3 Italy Dyslipidemia Epidemiology Forecast (2017-2032)
5.3.4 Spain Dyslipidemia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Dyslipidemia Epidemiology Forecast (2017-2032)
5.4 Japan Dyslipidemia Epidemiology Forecast (2017-2032)
6 Dyslipidemia Market Overview – 7MM
6.1 Dyslipidemia Market Historical Value (2017-2023)
6.2 Dyslipidemia Market Forecast Value (2024-2032)
7 Dyslipidemia Market Landscape – 7MM
7.1 Dyslipidemia : Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Dyslipidemia Product Landscape
7.2.1 Analysis by End User
7.2.2 Analysis by Route of Administration
8 Dyslipidemia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Dyslipidemia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Dyslipidemia Market Segmentation – 7MM
11.1 Dyslipidemia Market by Disease Type
11.1.1 Market Overview
11.1.2 General dyslipidemia
11.1.3 Hyperlipidemia
11.1.4 Combined hyperlipidemia
11.1.5 Hypoalphalipoproteinemia
11.2 Dyslipidemia Market by Drug Type
11.2.1 Market Overview
11.2.2 Statin Drugs
11.2.3 Non-Statin Lipid–Lowering Drugs
11.3 Dyslipidemia Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Online pharmacy
11.3.4 Retail Pharmacy
11.3.5 Others
11.4 Dyslipidemia Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Clinics
11.4.5 Others
11.5 Dyslipidemia Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Dyslipidemia Market
12.1 Dyslipidemia Market Historical Value (2017-2023)
12.2 Dyslipidemia Market Forecast Value (2024-2032)
12.3 Dyslipidemia Market by Drug Type
12.4 Dyslipidemia Market by End User
13 EU-4 and United Kingdom Dyslipidemia Market
13.1 Dyslipidemia Market Historical Value (2017-2023)
13.2 Dyslipidemia Market Forecast Value (2024-2032)
13.3 Germany Dyslipidemia Market Overview
13.3.1 Dyslipidemia Market by Drug Type
13.3.2 Dyslipidemia Market by End User
13.4 France Dyslipidemia Market Overview
13.4.1 Dyslipidemia Market by Drug Type
13.4.2 Dyslipidemia Market by End User
13.5 Italy Dyslipidemia Market Overview
13.5.1 Dyslipidemia Market by Drug Type
13.5.2 Dyslipidemia Market by End User
13.6 Spain Dyslipidemia Market Overview
13.6.1 Dyslipidemia Market by Drug Type
13.6.2 Dyslipidemia Market by End User
13.7 United Kingdom Dyslipidemia Market Overview
13.7.1 Dyslipidemia Market by Drug Type
13.7.2 Dyslipidemia Market by End User
14 Japan Dyslipidemia Market
14.1 Dyslipidemia Market Historical Value (2017-2023)
14.2 Dyslipidemia Market Forecast Value (2024-2032)
14.3 Dyslipidemia Market by Drug Type
14.4 Dyslipidemia Market by End User
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer, Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Novartis AG
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 AstraZeneca plc
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Amgen, Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Abbott Laboratories
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Bayer AG
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co., Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bristol-Myers Squibb Company
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Mylan N.V.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Shionogi & Co., Ltd.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Catabasis Pharmaceuticals
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 DAIICHI SANKYO COMPANY, LIMITED
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Eli Lilly and Company
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 GlaxoSmithKline plc
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 ESPERION Therapeutics, Inc.
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Dyslipidemia Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 10.2 billion in 2023, driven by the emphasis on preventing cardiovascular diseases across the major markets.
The market is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032, likely to reach a market value of USD 18.2 billion by 2032.
The market demand is driven by the rising prevalence of sedentary lifestyles, obesity, increased substance indulgence, and unhealthy dietary habits.
The major market trend involves increasing investments in drug development and research activities to offer better solutions for patients.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
The disease type can be divided into General dyslipidemia, Hyperlipidemia, Combined hyperlipidemia, and Hypoalphalipoproteinemia.
The drug types can be divided into statin drugs and non-statin lipid–lowering drugs.
The distribution channels include hospital pharmacy, online pharmacy, and retail pharmacy, among others.
The end-users include hospitals, homecare, and specialty clinics, among others.
Key players involved in the market are Pfizer, Inc., Novartis AG, AstraZeneca plc, Amgen, Inc., Abbott Laboratories., Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Mylan N.V., Shionogi & Co., Ltd., Catabasis Pharmaceuticals, DAIICHI SANKYO COMPANY, LIMITED, GlaxoSmithKline plc, ESPERION Therapeutics, Inc., and Eli Lilly and Company.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER